Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-NY-ESO-1-TCR-IL-15-transduced cord blood-derived natural killer cells

A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) that have been engineered to express a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human cancer-testis antigen NY-ESO-1 and interleukin-15 (IL-15), with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-NY-ESO-1-TCR-IL-15-transduced CB-derived NKs target, bind to and induce selective cytotoxicity in NY-ESO-1-expressing tumor cells. NY-ESO-1 is found in normal testis and on the surface of various tumor cell types. IL-15 is a pro-survival cytokine that promotes persistence of multiple lymphocyte lineages and potentiates the immune response against tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic anti-NY-ESO-1 TCR-transduced IL-15-expressing CB-derived NK cells
cord blood-derived NK cells genetically engineered with NY-ESO-1 TCR/IL-15 NKs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search